11/4
08:09 am
canf
Can-Fite BioPharma (NYSE:CANF) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
Low
Report
Can-Fite BioPharma (NYSE:CANF) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.